Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Major Shareholder Sells $39,015,179.28 in Stock

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) major shareholder Orbimed Advisors Llc sold 860,123 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $45.36, for a total value of $39,015,179.28. Following the completion of the transaction, the insider owned 219,405 shares of the company’s stock, valued at $9,952,210.80. The trade was a 79.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Orbimed Advisors Llc also recently made the following trade(s):

• On Monday, June 15th, Orbimed Advisors Llc sold 281,408 shares of Bitwise MARA Option Income Strategy ETF stock. The shares were sold at an average price of $45.02, for a total value of $12,668,988.16.

Bitwise MARA Option Income Strategy ETF Stock Performance

NYSEARCA:IMRA traded down $0.56 during mid-day trading on Wednesday, reaching $17.03. The stock had a trading volume of 604 shares, compared to its average volume of 5,314. The stock has a market capitalization of $3.24 million, a P/E ratio of 340.60 and a beta of 2.88. The firm has a 50 day moving average price of $16.69 and a two-hundred day moving average price of $15.74. Bitwise MARA Option Income Strategy ETF has a one year low of $11.99 and a one year high of $54.94.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.